Key result
Allele-specific siRNA reduces mutant TNNT2 protein expression by ~89% in HEK293T cells.
Why the study?
Autosomal dominant TNNT2 mutations cause hypertrophic and dilated cardiomyopathy, and allele-specific RNA interference holds promise for silencing mutant alleles while sparing wild-type alleles.
Does allele-specific silencing by RNA interference specifically knockdown R92Q and R173W mutant TNNT2 alleles in vitro?
Does allele-specific silencing by RNA interference specifically knockdown R92Q and R173W mutant TNNT2 alleles in vitro?
Allele-specific silencing by RNA interference successfully knocks down R92Q and R173W mutant TNNT2 alleles in vitro, providing a basis for potential therapeutic applications in cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for allele-specific RNAi in TNNT2 cardiomyopathy; leaves open translation to in vivo models or patients.
Autosomal dominant mutations in sarcomere proteins such as the cardiac troponin T ( TNNT2) are the main genetic causes of human hypertrophic cardiomyopathy and dilated cardiomyopathy. Allele-specific silencing by RNA interference (ASP-RNAi) holds promise as a therapeutic strategy for downregulating a single mutant allele with minimal suppression of the corresponding wild-type allele. Here, we propose ASP-RNAi as a possible strategy to specifically knockdown mutant alleles coding for R92Q and R173W mutant TNNT2 proteins, identified in hypertrophic and dilated cardiomyopathy, respectively. Different siRNAs were designed and validated by luciferase reporter assay and following analysis in HEK293T cells expressing either the wild-type or mutant TNNT2 alleles. This study is the first exploration of ASP-RNAi on TNNT2-R173W and TNNT2-R92Q mutations in vitro and gives a base for further application of allele silencing as a therapeutic treatment for TNNT2-mutation-associated cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Migliore et al. (2022) studied Hypertrophic and dilated cardiomyopathy (TNNT2 mutations). Allele-specific silencing by RNAi (ASP-RNAi) targeting TNNT2 mutations vs. Non-silencing control siRNA was evaluated on Reduction in R92Q mutant TNNT2 protein expression (p=<0.0000005). Allele-specific silencing by RNA interference using siRNAs with a single-base mismatch significantly reduced R92Q and R173W mutant TNNT2 protein expression by 88.8% and 92.7% in HEK293T cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: